MX2023000314A - Formulaciones farmaceuticas transdermicas de cannabinoides. - Google Patents

Formulaciones farmaceuticas transdermicas de cannabinoides.

Info

Publication number
MX2023000314A
MX2023000314A MX2023000314A MX2023000314A MX2023000314A MX 2023000314 A MX2023000314 A MX 2023000314A MX 2023000314 A MX2023000314 A MX 2023000314A MX 2023000314 A MX2023000314 A MX 2023000314A MX 2023000314 A MX2023000314 A MX 2023000314A
Authority
MX
Mexico
Prior art keywords
cannabinoids
pharmaceutical formulations
transdermal pharmaceutical
transdermal
nabilone
Prior art date
Application number
MX2023000314A
Other languages
English (en)
Spanish (es)
Inventor
Nisarg Modi
Fotios M Plakogiannis
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of MX2023000314A publication Critical patent/MX2023000314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023000314A 2020-08-17 2021-08-13 Formulaciones farmaceuticas transdermicas de cannabinoides. MX2023000314A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066386P 2020-08-17 2020-08-17
US202163229021P 2021-08-03 2021-08-03
PCT/IB2021/057483 WO2022038479A1 (en) 2020-08-17 2021-08-13 Transdermal pharmaceutical formulations of cannabinoids

Publications (1)

Publication Number Publication Date
MX2023000314A true MX2023000314A (es) 2023-02-22

Family

ID=80223734

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023000314A MX2023000314A (es) 2020-08-17 2021-08-13 Formulaciones farmaceuticas transdermicas de cannabinoides.
MX2023000316A MX2023000316A (es) 2020-08-17 2021-08-13 Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000316A MX2023000316A (es) 2020-08-17 2021-08-13 Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson.

Country Status (8)

Country Link
US (3) US20220047541A1 (enExample)
EP (2) EP4196114A4 (enExample)
JP (2) JP2023537675A (enExample)
CN (2) CN115884761A (enExample)
AU (2) AU2021328741A1 (enExample)
CA (2) CA3187588A1 (enExample)
MX (2) MX2023000314A (enExample)
WO (2) WO2022038479A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
EP4046630A1 (en) * 2021-02-18 2022-08-24 LTS Lohmann Therapie-Systeme AG Tts-formulation with thc
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
AU2022260813A1 (en) * 2021-04-22 2023-10-26 Pike Therapeutics Inc. Transdermal pharmaceutical formulations for the treatment of chronic pain
US20230059204A1 (en) * 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
GB202206000D0 (en) * 2022-04-25 2022-06-08 Univ Stellenbosch Leonotis leonurus extracts as a chemoprotectant and post-chemotherapeutic agent
US20240024253A1 (en) * 2022-07-21 2024-01-25 Pike Therapeutics Inc. Continuous Drug Delivery Systems and Methods
CN116077419B (zh) * 2023-02-24 2023-10-27 丽珠集团新北江制药股份有限公司 一种犬用盐酸司来吉兰透皮吸收剂及其制备方法
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation
CN116617161B (zh) * 2023-07-26 2023-10-24 中国科学院理化技术研究所 一种包含大麻二酚混悬液的可溶性微针及其制备方法
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6617356B2 (en) * 2000-01-03 2003-09-09 Naturally Scientific Inc Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2008006226A1 (en) * 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
EP2476414B1 (en) * 2009-09-07 2015-03-04 NIPRO Patch Co., Ltd. Transdermally absorbable preparation
BR112013001422A2 (pt) * 2010-07-20 2019-09-24 Phytopharm Plc metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
EP3509585B1 (en) * 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
JP7225103B2 (ja) * 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
CA3064782A1 (en) * 2017-05-26 2018-11-29 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
EP3678647A1 (en) * 2017-09-05 2020-07-15 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system for the transdermal administration of rivastigmine
JOP20200045A1 (ar) * 2017-09-19 2020-02-27 Zynerba Pharmaceuticals Inc كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
US11141172B2 (en) * 2018-04-11 2021-10-12 Globus Medical, Inc. Method and apparatus for locking a drill guide in a polyaxial hole
CN112996491A (zh) * 2018-10-15 2021-06-18 阿姆农·瓦尔迪 缓释大麻素及其产品
US11660283B2 (en) * 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
EP3906025A4 (en) * 2019-01-04 2022-09-21 Columbia Care LLC CANNABINOID TOPICAL FORMULATIONS
US10842758B1 (en) * 2019-06-18 2020-11-24 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations containing cannabidiol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
AU2021328742A1 (en) 2023-02-02
EP4196113A1 (en) 2023-06-21
EP4196114A1 (en) 2023-06-21
EP4196114A4 (en) 2024-10-30
US20250186363A1 (en) 2025-06-12
CA3187588A1 (en) 2022-02-24
JP2023537840A (ja) 2023-09-06
EP4196113A4 (en) 2024-04-03
CN115884761A (zh) 2023-03-31
WO2022038475A1 (en) 2022-02-24
US20220047525A1 (en) 2022-02-17
WO2022038479A1 (en) 2022-02-24
US20220047541A1 (en) 2022-02-17
CN115884760A (zh) 2023-03-31
JP2023537675A (ja) 2023-09-05
AU2021328741A1 (en) 2023-02-02
CA3187582A1 (en) 2022-02-24
MX2023000316A (es) 2023-02-22

Similar Documents

Publication Publication Date Title
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
BR112017003186A2 (pt) composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2025002790A (es) Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
JOP20190058B1 (ar) مشتقات كرومان، أيزوكرومان وداي هيدرو أيزو بنزوفوران كمُعدلات تفارغية سالبة mGluR2، تركيبات، واستخدامها
MX2021002611A (es) Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.
EP4480492A3 (en) Novel insulin analogues and uses thereof
BR112021000183A8 (pt) Preparação medicinal para uso externo
BR112023005536A2 (pt) Medicamento, composição farmacêutica e método para a prevenção ou tratamento de dermatite atópica, e, uso de um composto
BR112022023318A2 (pt) Abridores do canal de potássio maxi-k para o tratamento de distúrbios associados ao x frágil
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa